1 / 61

CARDIOVASCULAR DRUGS

CARDIOVASCULAR DRUGS. Reference: Pharmacology in Rehabilitation 4th Edition. Charles D. Ciccone , PT, PhD. Diuretics. Diuretics increase the formation and excretion of urine.

uttara
Download Presentation

CARDIOVASCULAR DRUGS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. CARDIOVASCULAR DRUGS

  2. Reference:Pharmacology inRehabilitation4th Edition Charles D. Ciccone, PT, PhD

  3. Diuretics

  4. Diuretics increase the formation and excretion of urine. increase the renal excretion of water and sodium, thus decreasing the volume of fluid within the vascular system.

  5. Classification of Diuretics ThiazideDiuretics. • act primarily on the early portion of the distal tubule of the nephron, where they inhibit sodium reabsorption. • the most frequently used type of diuretic Loop Diuretics. • act primarily on the ascending limb of the loop of Henle (hence the term inhibit the reabsorption of sodium and chloride from the nephron, thereby preventing reabsorption of the water that follows these electrolytes Potassium-Sparing Diuretics. prevent the secretion of potassium into the distal tubule. Normally, there is sodium-potassium exchange - sodium is reabsorbed and potassium is secreted. Potassium-sparing agents interfere with this exchange so potassium is spared from secretion and sodium is excreted. potassium sparing drugs have the advantage of reducing potassium loss and thus preventing hypokalemia.

  6. Classification of Diuretics Potassium-Sparing Diuretics. • prevent the secretion of potassium into the distal tubule. • Normally, there is sodium-potassium exchange - sodium is reabsorbed and potassium is secreted. • Potassium-sparing agents interfere with this exchange so potassium is spared from secretion and sodium is excreted. • Potassium sparing drugs have the advantage of reducing potassium loss and thus preventing hypokalemia.

  7. Adverse Effects of Diuretics • fluid depletion and electrolyte imbalance. • decreased extracellular fluid volume as well as produce sodium depletion (hyponatremia) and potassium depletion (hypokalemia).

  8. Sympatholytic Drugs

  9. Sympatholytic Drugs • an increase in sympathetic - a factor in essential hypertension. • sympatholytic agents - drugs that interfere with sympathetic discharge • classified according to where and how they interrupt sympathetic activity.

  10. Sympatholyticdrugs: beta-adrenergic blockers alpha-adrenergic blockers presynaptic adrenergic neurotransmitter depletors centrally acting drugs ganglionic blockers

  11. Beta Blockers • Beta-adrenergic blockers-a mainstay of antihypertensive • exert their primary effect on the heart- decrease heart rate and force of myocardial contraction. • (-) inotropic effect, (-) chronotropic effect = lowers BP

  12. Adverse Effects • Nonselective beta blockers (equal affinity for beta-1 and beta-2 receptors) may • produce bronchoconstriction in patients with asthma • Cardiovascular side effects include excessive depression of heart rate and myocardial contractility as well as orthostatic hypotension. • may impair glucose and lipid metabolism

  13. Alpha Blockers • block the alpha-1–adrenergic receptor on vascular smooth muscle = decrease in vascular resistance. • decreases total peripheral resistance

  14. Adverse Effects • When peripheral vascular resistance due to alpha blockers, the baroreceptor reflex often responds by generating a compensatory increase in heart rate (reflex tachycardia) • To prevent reflex tachycardia, a beta blocker may be administered with the alpha blocker • to negate the increase in heart rate

  15. Presynaptic Adrenergic Inhibitors inhibit the release of norepinephrine from the presynaptic terminals of peripheral adrenergic neurons Adverse Effects Orthostatic hypotension gastrointestinal disturbances such as nausea, vomiting and diarrhea.

  16. Centrally Acting Agents inhibit sympathetic discharge from the brainstem. Adverse Effects dry mouth, dizziness, and sedation.

  17. Vasodilators

  18. Vasodilators directly vasodilate the peripheral vasculature by decreasing peripheral vascular resistance. inhibit smooth-muscle Adverse Effects Reflex tachycardia dizziness, postural hypotension, weakness, nausea, fluid retention, and headache

  19. Inhibition of the renin-angiotensin system

  20. Renin-Angiotensin System Renin -formed in the renal juxtaglomerular cells in response to certain types of stimuli: • salt depletion • β2 stimulation • decrease in renal perfusion that might be found in hypotension or hypovolemia.

  21. renin mediates the formation of angiotensin-I in the liver. • When angiotensin-I reaches the lungs, it is converted by the angiotensin converting enzyme into angiotensin-II. • Angiotensin-II causes vasoconstriction, promotes the release of norepinephrine, and stimulates aldosterone production resulting in sodium and water retention.

  22. Additional effects of angiotensin-II include increased systemic vascular resistance, arterial blood pressure, and intravascular volume.

  23. Inhibition of the Renin-Angiotensin System two pharmacologic strategies: • inhibit the enzyme that converts angiotensin I to angiotensin II = angiotensin converting enzyme (ACE) inhibitors. • block angiotensin II receptors on various tissues = angiotensin II blockers

  24. Result: a decrease in norepinephrine levels, prevention of systemic vasoconstriction and decreased blood pressure. aldosterone production is no longer stimulated by Angiotensin II, which results in decreased intravascular volume.

  25. Adverse Effects allergic reaction - skin rash. persistent dry cough

  26. Calcium channel blockers

  27. Adverse Effects • may cause excessive vasodilation as evidenced by swelling in the feet and ankles • orthostatic hypotension.

  28. Nitrates

  29. Organic nitrates • dilate vascular smooth muscle • Nitrates are actually drug precursors (prodrugs) that become activated • when they are converted to nitric oxide within vascular smooth muscle Nitroglycerin- the most well known antianginal drug.

  30. Drugs Used for Overclotting

  31. Antithrombotic Drugs • anticoagulants affect the synthesis and function of clotting factors • antithrombotics primarily inhibit the function of platelets • prevent the formation of arterial clots, such as those • that cause coronary artery occlusion or cerebral infarction.

  32. Aspirin • suppresses platelet aggregation by inhibiting the synthesis of prostaglandins and thromboxanes. • inhibit the cyclooxygenase enzyme that initiates synthesis of prostaglandins and thromboxanes.

  33. Certain prostaglandins and thromboxanes, especially thromboxane A2, have a potent ability to induce platelet aggregation. • By inhibiting the synthesis of these proaggregation substances, aspirin prevents platelet-induced thrombus formation.

  34. very low aspirin doses = meaningful antithrombotic effect • adequate antithrombotic effects with one baby aspirin tablet each day • During the acute phase of an infarction, aspirin is critical in helping to limit the progression of platelet-induced occlusion, reducing the extent of damage to the myocardium

  35. Adverse Effects of Antithrombotic Drugs • aspirin increases risk of bleeding • may cause gastric irritation • high doses of aspirin may be toxic to the liver and kidneys

  36. Thrombolytic Drugs • Thrombolytics facilitate the breakdown and dissolution of clots formed. • activate conversion of plasminogen (profibrinolysin) to plasmin (fibrinolysin) • used to dissolve clots that have already formed, thus reopening occluded blood vessels.

  37. extremely valuable in treating acute myocardial infarction. • When administered at infarction onset, these drugs can reestablish • blood flow through occluded coronary vessels, preventing or reversing myocardial damage decreasing morbidity /mortality

  38. can help reopen occluded coronary vessels when administered within 12 hours after symptom onset. • Thrombolytics produce best results when administered soon after the symptom onset.

  39. Streptokinase and Urokinase both cause activation of plasmin. Streptokinase indirectly activates plasmin (fibrinolysin) Urokinase directly converts plasminogen to plasmin

  40. Adverse Effects of Thrombolytic Drugs Hemorrhage is the major adverse effect associated with thrombolytic agents.

More Related